Browse the evidence

Semaglutide improves glycemic control and metabolic parameters in patients with Type 2 Diabetes and obesity.

For those with Type 2 Diabetes, semaglutide helps manage blood sugar and aids in weight loss, though the weight loss effect may be more modest compared to non-diabetic patients.

Semaglutide at its maximum tolerated dose (MTD) is associated with the highest odds of treatment discontinuation due to adverse events among all tested regimens, including tirzepatide MTD.

If you choose semaglutide at its maximum dose, be aware that you have the highest statistical risk of stopping the medication due to side effects compared to other options in this study. Monitor your tolerance closely and communicate with your provider immediately if side effects become unmanageable.

Early Time-Restricted Eating (eTRE) with an 8-hour window (8 am - 4 pm) does NOT produce significantly greater weight loss than a calorie-restricted Mediterranean diet (MedDiet) in adults with obesity.

Early time-restricted eating (8 am - 4 pm) with a 600-calorie deficit did not result in significantly greater weight loss than a standard Mediterranean diet in this study. You may not see extra benefits from this specific timing strategy.

Use of GLP-1 receptor agonists (GLP1-RAs) is not associated with an increased risk of thyroid cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

If you have type 2 diabetes and are considering a GLP-1 medication like Ozempic or Wegovy, current large-scale evidence suggests it does not increase your risk of thyroid cancer compared to other common diabetes drugs. While rodent studies showed thyroid effects, this has not been observed in human population studies.

Self-reported dietary energy intake in population surveys is systematically biased by macronutrient composition, specifically under-reporting protein and over-reporting fat relative to actual expenditure.

When analyzing dietary data or tracking your own intake, do not assume that your macronutrient ratios are accurate if your total calorie count is off. People who under-report calories tend to under-report protein and over-report fat. This bias distorts the perceived relationship between diet and health outcomes, meaning 'healthy' diets may appear even healthier than they are in self-reported data.

GLP-1 receptor agonists (GLP-1 RAs) significantly increase the risk of gastrointestinal adverse events, specifically intestinal obstruction and perioperative aspiration, due to delayed gastric emptying.

If you are taking a GLP-1 medication (like Ozempic or Wegovy) and have surgery or an endoscopy, tell your medical team. You may need to adjust your fasting time or pause the medication to prevent stomach contents from entering your lungs, which is a known risk of these drugs.

GLP-1 receptor agonists are associated with an increased risk of gallbladder and biliary tract diseases, particularly with weight-loss focused dosing and specific agents like liraglutide.

Be aware that GLP-1 medications can increase the risk of gallstones, especially if you are losing weight rapidly. Report any abdominal pain to your doctor. This risk is higher with weight-loss doses compared to diabetes doses.

Current evidence does not support a significant increased risk of acute pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists in human populations, despite early animal studies and spontaneous reports.

You do not need to worry about developing pancreatitis or pancreatic cancer from GLP-1 medications. Large studies have confirmed they are safe in this regard, although you should stop the medication if you experience severe abdominal pain.

Polygenic scores for BMI and Type 2 Diabetes do not significantly predict weight loss outcomes in patients treated with GLP-1 receptor agonists.

If you are taking a GLP-1 RA (like semaglutide or liraglutide), your common genetic risk for obesity does not predict how much weight you will lose. The drug's effectiveness is largely independent of your polygenic score for BMI or Type 2 Diabetes. Focus on adherence and lifestyle factors rather than genetic testing for treatment selection.

GLP-1 RA treatment results in significantly lower weight loss in individuals of African and admixed American ancestry compared to European ancestry, after adjusting for baseline factors.

If you are of African or admixed American ancestry, you may experience slightly less weight loss from GLP-1 RA drugs compared to European ancestry individuals, even when adjusting for baseline weight and other factors. This may be due to biological or socioeconomic factors. Close monitoring and potential dose adjustments may be necessary.

Higher plasma levels of the gut microbiome-derived metabolite Trimethylamine-N-oxide (TMAO) are associated with a significantly higher risk of incident atherosclerotic cardiovascular disease (ASCVD) in a diverse, community-based population free of prior cardiovascular disease.

This study suggests that higher levels of TMAO, a byproduct of gut bacteria processing nutrients like red meat and eggs, are linked to a higher risk of heart disease. While it doesn't tell you to eliminate these foods, it highlights the importance of your gut health and kidney function. If you have risk factors for heart disease, discussing your diet and TMAO levels with your doctor might be worthwhile, especially if you have reduced kidney function.

GLP-1 receptor agonists (GLP-1RAs) induce pre-ingestive, cognitive satiation by activating dorsomedial hypothalamus (DMH) GLP-1R neurons, which inhibit arcuate nucleus AgRP neurons to terminate meals before ingestion begins.

GLP-1 medications work partly by changing how your brain processes food cues before you even eat. By activating specific brain regions (DMH), they signal 'stop' based on anticipation, not just stomach fullness. This cognitive effect helps reduce meal size and frequency, contributing to weight loss beyond just slowing digestion.

Co-ingesting protein with carbohydrate during endurance exercise does not improve performance or glycogen resynthesis when carbohydrate recommendations are met.

Do not rely on adding protein to your in-exercise nutrition for performance or glycogen storage. Stick to recommended carbohydrate intakes. Save protein for post-exercise recovery.

Multi-receptor incretin drugs are associated with an increased risk of adverse events (primarily gastrointestinal) compared to placebo, but do not significantly increase the risk of serious adverse events.

Be aware that multi-receptor incretin drugs commonly cause gastrointestinal side effects like nausea, which may lead to discontinuation for some. However, the risk of serious health events is not significantly higher than placebo. Discuss potential side effects with your doctor and report any severe or persistent symptoms.

Obesity increases the risk of various cancers, including breast, endometrial, ovarian, kidney, thyroid, and gastrointestinal cancers, through mechanisms involving chronic inflammation, adipokine secretion, and epigenetic dysregulation.

Obesity increases your risk of several types of cancer, including breast, endometrial, and gastrointestinal cancers. This risk is driven by chronic inflammation and hormones secreted by fat tissue.

Acute exercise (both HIIT and MICT) results in more phosphosite down-regulation than up-regulation, suggesting that acute exercise involves the inhibition of kinase activity and/or activation of phosphatases.

Exercise doesn't just turn things on; it also turns things off. This balance is crucial for adaptation. Don't assume more activation is always better; regulation (inhibition) is part of the process.

Endogenous gut-derived GLP-1, secreted in response to nutrients or non-caloric stimuli (like gastrointestinal distension), regulates feeding behavior and glucose metabolism via vagal sensory nerves without causing the adverse effects (nausea/vomiting) associated with GLP-1 receptor agonists.

You can influence your GLP-1 levels naturally. Eating GLP-1-stimulating foods (meat, fish, salad) first, followed by a wait before carbs, improves glycemic control and weight loss. Gastrointestinal distension from bulky, low-energy-density foods also triggers beneficial GLP-1 secretion via vagal nerves without causing nausea.

Preoperative use of GLP-1 receptor agonists does not improve long-term weight loss, diabetes remission, or surgical safety outcomes in patients undergoing metabolic bariatric surgery compared to those who do not use GLP-1s.

If you are considering bariatric surgery, using GLP-1 drugs (like Ozempic or Wegovy) beforehand does not appear to make your surgery more successful or your weight loss better in the long run. In fact, it may just delay getting the more effective surgical treatment. If you are experiencing side effects from these drugs or they aren't working well enough, switching to surgery is a valid and effective path, but don't expect the drugs to give you a 'head start' on your results.

GLP-1 receptor agonists (GLP-1 RAs) are primarily prescribed as anti-diabetic medications (ADMs) rather than anti-obesity medications (AOMs), with 71.8% of first-time prescriptions designated for diabetes management and only 28.2% for obesity.

While GLP-1 medications like semaglutide and tirzepatide are famous for weight loss, the vast majority of prescriptions (over 70%) are for treating Type 2 Diabetes. If you are seeking these medications for weight loss, you may face higher costs and insurance hurdles because they are not primarily covered for obesity in many cases.

There is a significant disparity in medication initiation rates between diabetes and obesity indications, with 72.2% of diabetes prescriptions filled within 60 days compared to only 46.8% of obesity prescriptions.

If you are prescribed a GLP-1 for weight loss, be aware that you are less likely to fill the prescription than someone prescribed for diabetes. This is due to insurance coverage gaps, not a lack of desire to treat. Check your coverage status before the prescription is written to avoid delays.

Tirzepatide has surpassed semaglutide as the most commonly prescribed first-time GLP-1 RA medication in the US as of September 2025.

Tirzepatide is now the most frequently prescribed first-time GLP-1 medication in the US, overtaking semaglutide. This reflects changing prescribing preferences among physicians.

Downregulation of the transcription factor NR4A3 in human skeletal muscle, mimicking physical inactivity, impairs glucose oxidation and protein synthesis while increasing fatty acid oxidation and lactate production, leading to muscle atrophy.

Physical inactivity actively suppresses a key protein (NR4A3) in your muscles, which shifts your metabolism away from burning glucose and toward making lactate, while simultaneously shutting down muscle building signals. This molecular change is a primary driver of muscle loss during sedentary periods. While this study was done on cells, it suggests that maintaining NR4A3 levels (e.g., through movement) is crucial for preserving muscle mass and metabolic health, and future therapies might target this pathway.

Dual GLP1R/GIPR agonists achieve superior glucose lowering and weight reduction compared to single GLP1R agonists through specific engagement of pancreatic islet cells (beta, alpha, delta) and circumventricular organ neurons, rather than through enhanced brain penetration.

Dual GLP1/GIP agonists work better than single GLP1 drugs because they target specific cells in the pancreas (beta, alpha, delta) and specific neurons in the brain's edge (circumventricular organs), not because they penetrate the brain deeper. This targeted engagement drives superior glucose and weight outcomes.

Dual GLP1R/GIPR agonists label pancreatic beta, alpha, and delta cells with varying intensity (beta > alpha = delta), engaging distinct receptor nanodomains that differ from those targeted by single agonists.

Dual agonists affect multiple hormone-secreting cells in the pancreas, with the strongest effect on insulin-secreting beta cells, followed by glucagon-secreting alpha and somatostatin-secreting delta cells.